
Sign up to save your podcasts
Or


Exploring the ACE Index in Acute Ulcerative Colitis
Rebecca K Grant, Gareth-Rhys Jones, Nikolas Plevris, Ruairi W Lynch, Philip W Jenkinson, Charlie W Lees, Thomas A Manship, Fiona A M Jagger, William M Brindle, Mrithula Shivakumar, Jack Satsangi, Ian D R Arnott
Background: Intravenous (IV) steroids remain the first-line treatment for patients with acute ulcerative colitis (UC). However, 30% of patients do not respond to steroids, requiring second-line therapy and/or surgery. There are no existing indices that allow physicians to predict steroid nonresponse at admission. We aimed to determine if admission biochemical and endoscopic values could predict response to IV steroids.
Methods: All admissions for acute UC (ICD-10 K51) between November 1, 2011, and October 31, 2016 were identified. Case note review confirmed diagnosis; clinical, endoscopic, and laboratory data were collected. Steroid response was defined as discharge home with no further therapy for active UC. Nonresponse was defined as requirement for second-line therapy or surgery. Univariate and binary logistic regression analyses were employed to identify factors associated with steroid nonresponse.
Results: Two hundred and thirty-five acute UC admissions were identified, comprising both acute severe and acute nonsevere UC; 155 of the 235 patients (66.0%) …
Here to talk about some of the cellular changes associated with aging, how these changes manifest clinically as we age, and emerging nutritional interventions to target these changes is Dr. Eric Verdin, the President and Chief Executive Officer of the Buck Institute for Research on Aging.
What do we need to know about the relationship between biomarker cutoff levels and mucosal healing? Dr. Xiaohong Wang, a post-doctoral fellow at the Center for Ultrasound Research & Translation in the Department of Radiology at Massachusetts General Hospital, discusses the results of the CALM study.
Hospitalizations due to acute heart failure represent a growing healthcare problem and a large economic burden. Iron deficiency, irrespective of anemia, is prevalent among this population and is associated with a high risk for increased mortality and rehospitalization. Tune in to discover the latest data from the AFFIRM-AHF trial. What does this new information reveal about treatment with intravenous iron in patients with acute heart failure?
The outbreak of the COVID-19 pandemic has pushed healthcare professionals to adjust the way they treat patients with chronic conditions like diabetes. Tune in to hear Drs. John Anderson, John Buse, Carol Wysham share their experience caring for patients with diabetes amid the pandemic.
Effective communication is essential to improving the patient-provider relationship. What is the best approach a physician can take when speaking to patients with IBS? Dr. Peter Buch will discuss valuable communication strategies with Dr. Douglas Drossman, president of the Rome Foundation.
Dive into the DIVINE study with Dr. Todd Rice, a pulmonologist and Associate Professor of Medicine at Vanderbilt University Medical Center. Dr. Rice explores the factors that have prompted a reassessment of macronutrient roles in critical illness and the results from the DIVINE study, which investigated whether a very high protein and lower carbohydrate enteral nutrition formula could facilitate improved glucose control while avoiding worsening hyperglycemia.
Despite evidence and guideline recommendations, renin-angiotensin-aldosterone system inhibitor (RAASi) therapy tends to be used suboptimally among patients with heart failure (HF), particularly in patients with chronic kidney disease (CKD). What are the real-world factors that influence RAASi treatment decisions in patients with HF who have or are at risk for hyperkalemia? Hear about how the CARE HK in HF study is being designed to explore the real-world data surrounding this question and its associated impact on outcomes.
A Specific Mutation in Muc2 Determines Early Dysbiosis in Colitis-Prone Winnie Mice
Marina Liso, Stefania De Santis, Giulio Verna, Manuela Dicarlo, Maria Calasso, Angelo Santino, Isabella Gigante, Rajaraman Eri, Sathuwarman Raveenthiraraj, Anastasia Sobolewski, Valeria Palmitessa, Antonio Lippolis, Mauro Mastronardi, Raffaele Armentano, Grazia Serino, Maria De Angelis, Marcello Chieppa
Background: Inflammatory bowel disease (IBD), including Crohn disease (CD) and ulcerative colitis (UC), is a multifactorial disorder characterized by chronic inflammation and altered gut barrier function. Dysbiosis, a condition defined by dysregulation of the gut microbiome, has been reported in patients with IBD and in experimental models of colitis. Although several factors have been implicated in directly affecting gut microbial composition, the genetic determinants impacting intestinal dysbiosis in IBD remain relatively unknown.
Methods: We compared the microbiome of normal, uninflamed wild-type (WT) mice with that of a murine model of UC (ie, Winnie strain). Winnie mice possess a missense mutation in Muc2 that manifests in altered mucus production as early as 4 weeks of …
Despite the increasing prevalence of home enteral nutrition over the last few decades, there has not been an equal rise in the number of studies being conducted in this population, which makes it difficult to develop guidelines and answer key clinical questions. So to help address this gap, the home enteral nutrition team at Mayo Clinic conducted a retrospective analysis of patients who utilized peptide-based diets, and now, Dr. Manpreet Mundi is here to share the results of that analysis.
From the publisher's feed